Hepatocellular carcinoma

What Is Hepatocellular Carcinoma?

Hepatocellular carcinoma is the most common type of primary liver cancer, accounting for up to ninety percent of cases in which cancer originates directly within the liver rather than spreading there from another part of the body.¹

Hepatocellular carcinoma typically develops within the setting of chronic liver disease, most often arising after years of ongoing liver damage that progresses through stages of inflammation and scarring before cancer ultimately develops.²

Cirrhosis, a condition marked by extensive scarring of the liver, represents the single largest risk factor for hepatocellular carcinoma, present in an estimated seventy to ninety percent of people diagnosed with the disease.³

Cirrhosis of any cause is the single largest risk factor in the development of hepatocellular carcinoma, present in seventy to ninety percent of those who develop primary liver cancer.
National Center for Biotechnology Information

Symptoms

Hepatocellular carcinoma frequently produces no symptoms in its early stages, which is part of why regular screening is recommended for people with known risk factors such as cirrhosis or chronic viral hepatitis.

As the disease progresses, symptoms can include unintended weight loss, abdominal pain or swelling, loss of appetite, fatigue, and jaundice, a yellowing of the skin and eyes caused by impaired liver function.

Because many of these symptoms overlap considerably with those of underlying liver disease itself, distinguishing new cancer related symptoms from preexisting chronic liver disease can be challenging without imaging or other targeted testing.

Causes

The majority of hepatocellular carcinoma cases develop through a gradual progression, beginning with acute liver injury, advancing through various stages of chronic hepatitis, and eventually reaching cirrhosis before cancer ultimately develops.²

Chronic viral hepatitis represents the most important cause worldwide, with chronic hepatitis B and hepatitis C infections together accounting for approximately eighty percent of cases globally, and hepatitis B alone responsible for more than half of all cases.¹

Beyond viral hepatitis, hepatocellular carcinoma is also associated with alcoholic liver disease, metabolic related fatty liver disease, and, in certain regions, exposure to a toxin called aflatoxin found in improperly stored food.²

Risk Factors

Chronic hepatitis B or hepatitis C infection, autoimmune hepatitis, chronic alcohol use, obesity, and diabetes mellitus all represent established risk factors for developing hepatocellular carcinoma.³

In the United States specifically, additional recognized risk factors include being born between nineteen forty five and nineteen sixty five, male sex, Hispanic ethnicity, metabolic syndrome, excessive alcohol use, and smoking.³

Among people with cirrhosis caused by chronic hepatitis B or hepatitis C infection, the annual risk of developing hepatocellular carcinoma ranges from approximately two to five percent, underscoring the importance of regular surveillance in this high risk population.³

Complications

As hepatocellular carcinoma advances, tumors can grow large enough to significantly impair remaining liver function, worsening symptoms related to underlying cirrhosis and liver failure.

In rare but serious cases, tumor tissue can extend directly into major blood vessels, including the veins that carry blood from the liver back to the heart, occasionally reaching as far as the right side of the heart itself.⁴

Because hepatocellular carcinoma so often develops in the setting of preexisting cirrhosis, patients frequently face the combined burden of both cancer progression and declining liver function, complicating treatment decisions and overall prognosis.

Treatment

Surgical tumor removal, whether through partial liver resection or full liver transplantation, remains the only treatment approach with true curative potential for hepatocellular carcinoma.⁵

Thermal ablation offers another potentially curative option for carefully selected patients, though its curative potential is generally limited to smaller tumors, typically under two centimeters in size.⁵

Unfortunately, only about fifteen percent of all hepatocellular carcinoma cases are suitable for surgical treatment, meaning that many patients instead receive noncurative treatments, including intraarterial therapy, radiation, or systemic therapy, aimed at slowing disease progression and preserving quality of life.⁵

Prevention

Vaccination against hepatitis B represents one of the most effective, widely available strategies for preventing hepatocellular carcinoma, directly addressing one of its leading underlying causes.¹

For people already living with chronic hepatitis B or hepatitis C, antiviral treatment can meaningfully reduce the risk of progression to cirrhosis and, ultimately, hepatocellular carcinoma.¹

Limiting alcohol consumption and managing metabolic conditions such as obesity and diabetes further support liver health and help reduce the risk of developing the chronic liver damage that so often precedes hepatocellular carcinoma.³

Why Visual Communication Matters for Hepatocellular Carcinoma

Explaining how years of chronic liver injury can gradually progress from inflammation to cirrhosis to cancer requires visuals that make this slow, multistage disease process understandable to patients managing longterm liver disease.

Pharmaceutical companies, oncology and hepatology practices, and patient education organizations rely on clear illustration and animation to explain hepatocellular carcinoma and support informed treatment decisions.

• Illustrating the progression from chronic hepatitis to cirrhosis to liver cancer
• Animating how viral hepatitis and other risk factors damage liver tissue over time
• Explaining surgical resection, transplantation, and ablation treatment options
• Visualizing tumor growth and its effect on remaining liver function
• Supporting patient education on screening for high risk populations
• Creating training materials for hepatology, oncology, and surgical clinicians

How Biotic Artlab Supports Hepatocellular Carcinoma Communication

We work with pharmaceutical companies, oncology and hepatology practices, and patient advocacy organizations to create scientifically accurate visuals that make hepatocellular carcinoma and its treatment easier to understand.

• Custom 3D animations of chronic liver disease progression and cancer development
• Detailed illustrations of surgical resection, transplantation, and ablation procedures
• Patient facing materials on hepatitis vaccination and screening for high risk groups
• Educational content addressing cirrhosis and its relationship to liver cancer
• Clinical training materials for hepatology, oncology, and surgical teams
• Conference presentations and marketing visuals for liver health audiences

Frequently Asked Questions

What is the leading risk factor for hepatocellular carcinoma?

Cirrhosis of any cause represents the single largest risk factor, present in seventy to ninety percent of people diagnosed with the disease.³

Can hepatitis infection lead to liver cancer?

Yes, chronic hepatitis B and hepatitis C infections together account for approximately eighty percent of hepatocellular carcinoma cases worldwide.¹

Does hepatocellular carcinoma cause early symptoms?

Usually not. Early disease is frequently asymptomatic, which is why regular screening is recommended for people with cirrhosis or chronic viral hepatitis.

What is the only curative treatment for hepatocellular carcinoma?

Surgical tumor removal, through either partial liver resection or liver transplantation, remains the only treatment with true curative potential.⁵

Can hepatocellular carcinoma be prevented?

Hepatitis B vaccination, antiviral treatment for chronic hepatitis, limiting alcohol use, and managing obesity and diabetes can all meaningfully reduce risk.¹

Why is only a small percentage of cases treated with surgery?

Only about fifteen percent of hepatocellular carcinoma cases are suitable for surgical treatment, often because of tumor size, location, or the extent of underlying liver disease.⁵

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to hepatocellular carcinoma or liver health, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Risk Factors and Prevention of Viral Hepatitis Related Hepatocellular Carcinoma.
2. National Center for Biotechnology Information. Hepatocellular Carcinoma, Causes, Mechanism of Progression and Biomarkers.
3. National Center for Biotechnology Information. Risk Factors for Hepatocellular Carcinoma.
4. National Center for Biotechnology Information. Hepatocellular Carcinoma With Tumor Thrombus to the Hepatic Veins and the Right Atrium.
5. National Center for Biotechnology Information. Hepatocellular Carcinoma, Diagnosis and Operative Management.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.